Keywords: triangle, seeks, lift, halt, hiv, drug, pharmaceuticals
Triangle seeks to lift halt on HIV drug
Article | 13 June 2000
Triangle Pharmaceuticals has reported data from a Phase I/IIdose-escalation combination study of DMP-450, its cyclic urea-based HIV protease inhibitor, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
